1 Drescher, H. K., Weiskirchen, S. & Weiskirchen, R. Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). Cells 8, doi:10.3390/cells8080845 (2019).
2 Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. & Sanyal, A. J. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 24, 908-922, doi:10.1038/s41591-018-0104-9 (2018).
3 Pydyn, N., Miekus, K., Jura, J. & Kotlinowski, J. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis. Pharmacol Rep 72, 1-12, doi:10.1007/s43440-019-00020-1 (2020).
4 Koo, S. H. Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin Mol Hepatol 19, 210-215, doi:10.3350/cmh.2013.19.3.210 (2013).
5 Lee, Y. K., Park, J. E., Lee, M. & Hardwick, J. P. Hepatic lipid homeostasis by peroxisome proliferator-activated receptor gamma 2. Liver Res 2, 209-215, doi:10.1016/j.livres.2018.12.001 (2018).
6 Wang, L. F. et al. Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKalpha/SREBP1 signaling pathway. Lipids Health Dis 16, 82, doi:10.1186/s12944-017-0464-z (2017).
7 Musso, G., Gambino, R. & Cassader, M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 48, 1-26, doi:10.1016/j.plipres.2008.08.001 (2009).
8 Souza-Mello, V. Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease. World J Hepatol 7, 1012-1019, doi:10.4254/wjh.v7.i8.1012 (2015).
9 Seo, Y. J., Lee, K., Song, J. H., Chei, S. & Lee, B. Y. Ishige okamurae Extract Suppresses Obesity and Hepatic Steatosis in High Fat Diet-Induced Obese Mice. Nutrients 10, doi:10.3390/nu10111802 (2018).
10 Pandey, S., Cabot, P. J., Shaw, P. N. & Hewavitharana, A. K. Anti-inflammatory and immunomodulatory properties of Carica papaya. J Immunotoxicol 13, 590-602, doi:10.3109/1547691X.2016.1149528 (2016).
11 Santana, L. F. et al. Nutraceutical Potential of Carica papaya in Metabolic Syndrome. Nutrients 11, doi:10.3390/nu11071608 (2019).
12 Julianti, T. et al. HPLC-based activity profiling for antiplasmodial compounds in the traditional Indonesian medicinal plant Carica papaya L. J Ethnopharmacol 155, 426-434, doi:10.1016/j.jep.2014.05.050 (2014).
13 Brasil, G. A. et al. Antihypertensive effect of Carica papaya via a reduction in ACE activity and improved baroreflex. Planta Med 80, 1580-1587, doi:10.1055/s-0034-1383122 (2014).
14 Ma, H., Li, J., An, M., Gao, X. M. & Chang, Y. X. A powerful on line ABTS(+)-CE-DAD method to screen and quantify major antioxidants for quality control of Shuxuening Injection. Scientific reports 8, 5441, doi:10.1038/s41598-018-23748-x (2018).
15 Xie, W. & Chen, S. A nomogram for estimating the probability of nonalcoholic fatty liver disease in a Chinese population: A retrospective cohort study. Medicine (Baltimore) 99, e23049, doi:10.1097/MD.0000000000023049 (2020).
16 Lakhani, H. V. et al. Phenotypic Alteration of Hepatocytes in Non-Alcoholic Fatty Liver Disease. Int J Med Sci 15, 1591-1599, doi:10.7150/ijms.27953 (2018).
17 Hu, Y. et al. Acerola polysaccharides ameliorate high-fat diet-induced non-alcoholic fatty liver disease through reduction of lipogenesis and improvement of mitochondrial functions in mice. Food Funct 11, 1037-1048, doi:10.1039/c9fo01611b (2020).
18 Zhong, F., Zhou, X., Xu, J. & Gao, L. Rodent Models of Nonalcoholic Fatty Liver Disease. Digestion 101, 522-535, doi:10.1159/000501851 (2020).
19 Ye, J. et al. Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction. Therap Adv Gastroenterol 12, 1756284819879047, doi:10.1177/1756284819879047 (2019).
20 Skat-Rordam, J., Hojland Ipsen, D., Lykkesfeldt, J. & Tveden-Nyborg, P. A role of peroxisome proliferator-activated receptor gamma in non-alcoholic fatty liver disease. Basic Clin Pharmacol Toxicol 124, 528-537, doi:10.1111/bcpt.13190 (2019).
21 Jo, H. K., Kim, G. W., Jeong, K. J., Kim, D. Y. & Chung, S. H. Eugenol ameliorates hepatic steatosis and fibrosis by down-regulating SREBP1 gene expression via AMPK-mTOR-p70S6K signaling pathway. Biol Pharm Bull 37, 1341-1351, doi:10.1248/bpb.b14-00281 (2014).
22 Shimano, H. et al. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest 99, 846-854, doi:10.1172/JCI119248 (1997).
23 Grønning-Wang, L. M., Bindesbøll, C. & Nebb, H. I. The role of liver X receptor in hepatic de novo lipogenesis and cross-talk with insulin and glucose signaling. Lipid metabolism, 61-90 (2013).
24 Kohjima, M. et al. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med 21, 507-511 (2008).
25 Dai, J. et al. Chemoproteomics reveals baicalin activates hepatic CPT1 to ameliorate diet-induced obesity and hepatic steatosis. Proc Natl Acad Sci U S A 115, E5896-E5905, doi:10.1073/pnas.1801745115 (2018).
26 Montagner, A. et al. Liver PPARalpha is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Gut 65, 1202-1214, doi:10.1136/gutjnl-2015-310798 (2016).
27 Pawlak, M., Lefebvre, P. & Staels, B. Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol 62, 720-733, doi:10.1016/j.jhep.2014.10.039 (2015).
28 Reddy, J. K. & Rao, M. S. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 290, G852-858, doi:10.1152/ajpgi.00521.2005 (2006).
29 Liou, C. J. et al. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid beta-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice. Cell Physiol Biochem 49, 1870-1884, doi:10.1159/000493650 (2018).
30 Inamdar, S., Joshi, A., Malik, S., Boppana, R. & Ghaskadbi, S. Vitexin alleviates non-alcoholic fatty liver disease by activating AMPK in high fat diet fed mice. Biochem Biophys Res Commun 519, 106-112, doi:10.1016/j.bbrc.2019.08.139 (2019).
31 Kanuri, G. & Bergheim, I. In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD). International journal of molecular sciences 14, 11963-11980, doi:10.3390/ijms140611963 (2013).
32 Müller, F. A. & Sturla, S. J. Human in vitro models of nonalcoholic fatty liver disease. Current Opinion in Toxicology 16, 9-16 (2019).
33 Lee, M. R., Yang, H. J., Park, K. I. & Ma, J. Y. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice. Phytomedicine 55, 14-22, doi:10.1016/j.phymed.2018.07.008 (2019).
34 Ali, O., Darwish, H. A., Eldeib, K. M. & Abdel Azim, S. A. miR-26a Potentially Contributes to the Regulation of Fatty Acid and Sterol Metabolism In Vitro Human HepG2 Cell Model of Nonalcoholic Fatty Liver Disease. Oxid Med Cell Longev 2018, 8515343, doi:10.1155/2018/8515343 (2018).
35 Gomaraschi, M. et al. Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: Evidence in NAFLD patients and cell cultures. Biochim Biophys Acta Mol Cell Biol Lipids 1864, 158523, doi:10.1016/j.bbalip.2019.158523 (2019).
36 Xia, H. et al. Alpha-naphthoflavone attenuates non-alcoholic fatty liver disease in oleic acid-treated HepG2 hepatocytes and in high fat diet-fed mice. Biomed Pharmacother 118, 109287, doi:10.1016/j.biopha.2019.109287 (2019).
37 Park, Y. J., Lee, G. S., Cheon, S. Y., Cha, Y. Y. & An, H. J. The anti-obesity effects of Tongbi-san in a high-fat diet-induced obese mouse model. BMC Complement Altern Med 19, 1, doi:10.1186/s12906-018-2420-5 (2019).